698 results found | searching for "pharma"

First Previous 1 2 3 4 5 6 7 8 9 10 Next Last 
  • vamshee
  • https://precisionbusinessinsights.com/market-reports/orthopedic-braces-and-supports-market/ Orthopedic Braces And Supports Market: By Product Type (Knee Braces and Supports, Ankle Braces and Supports, Foot Walkers and Orthoses, Hip, Back, And Spine Braces and Support, Shoulder Braces and Supports, Elbow Braces and Supports, Hand & Wrist Braces and Supports, Facial Braces and Supports), By Type (Soft & Elastic Braces and Supports, Hard Braces and Supports, and Hinged Braces and Supports), By Application (Preventive Care, Ligament Injury, Post-operative Rehabilitation, Osteoarthritis, Compression Therapy, Others), By Distribution Channel (Hospitals and Surgical Centres, Orthopedic Clinics, Pharmacies & Retailers, E-commerce platforms, Others, and Geography
  • vamshee
  • https://precisionbusinessinsights.com/market-reports/wound-debridement-market/ Wound Debridement Market By Methodology (Biological, Enzymatic, Autolytic, Mechanical, and Sharp), Product (Gels, Ointment & Creams, Surgical Devices, Medical Gauzes, Ultrasonic Devices, and Others), Wound Type (Pressure Ulcers, Diabetic Foot Ulcers, Venous Leg Ulcers, Burn Wound, and Others), End User (Hospitals, Diabetic Clinics, Homecare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), And Geography
  • jameshebrew
  • The mRNA synthesis and manufacturing market is projected to be worth USD 1.5 billion by 2035, claims Roots Analysis Given the current technical and operational challenges associated with the manufacturing of mRNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the mRNA synthesis and contract manufacturing service providers. Roots Analysis has announced the addition of “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of offerings. Owing to the recent success and growing pipeline of mRNA-based products in the market, mRNA, as a therapeutic agent, has gained significant traction from the medical community. However, due to challenges, such as high capital requirement, stringent regulations and lack of technical expertise, outsourcing has become a preferred business model and CMOs are upgrading their existing capabilities and service portfolios to meet the increased demand for mRNA-based products. Key Market Insights Presently, 30+ companies claim to offer custom synthesis services for mRNA, globally. Majority of the service providers are mid-sized players (44%), followed by small (35%), large (12%) and very large players (9%). Additionally, more than 25% of the stakeholders were established post 2010. It is also worth mentioning that over 50% of the total players are based in North America, specifically in the US. More than 40 companies, across the globe, claim to provide contract manufacturing and fill / finish services for mRNA vaccines / therapeutics. Of the aforementioned players, nearly 85% of the contract manufacturing service providers are based in North America and Europe. Notably, more than 50% of the total players engaged in this space offer services for drug substance (APIs) manufacturing. Currently, more than 95 mRNA synthesis kits are available in the market. Close to 70% of the mRNA synthesis kits contain capping enzymes; of these, 96% use T7 RNA polymerase enzyme mix for the synthesis of modified mRNAs. It is worth highlighting that majority (54%) of the kit developers are small players. More than 170 clinical trials have been registered for the evaluation of mRNA-based therapeutics / vaccines, worldwide. The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 44%, during the period 2017-2022. Of the total number of trials registered, close to 22% have already been completed, while 46% of the studies are actively recruiting participants. Partnership activity within this domain has grown at a CAGR of 60%, between 2019 and 2022. Nearly 34% of the deals were inked in 2021. Majority of the instances captured in the report were manufacturing agreements, representing 22% of the total partnerships. Further, most of the intercontinental deals have been inked by players based in North America. North America and Europe are anticipated to capture close to 65% of the global market share, by 2035. The market in Asia Pacific is likely to grow at the highest CAGR during the period 2022-2035. In terms of type of product, drug substance (APIs) is expected to occupy a larger share (70%) of the overall mRNA synthesis and manufacturing service market in 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market/request-sample.html Key Questions Answered  What are the factors driving mRNA synthesis and manufacturing market?  How many players are providing services for custom synthesis of mRNAs?  How many players are offering mRNA contract manufacturing services for commercial purposes?  How many kits are available in the market for the synthesis of mRNA?  Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?  Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?  What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?  Who are the key players in mRNA synthesis and manufacturing market? The financial opportunity within the mRNA synthesis and manufacturing service market has been analysed across the following segments:  Type of Product  Drug substances (APIs)  Drug products (FDFs)  Application Area  mRNA-based vaccines  mRNA-based therapeutics  Therapeutic Area  Infectious diseases  Oncological disorders  Other diseases  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa  Rest of the World The research also includes detailed profiles of the key players (listed below) engaged in mRNA synthesis and manufacturing domain; each profile features a brief overview of the company, details related to its service portfolio (for mRNA synthesis and contract manufacturing service providers) / product portfolio (mRNA synthesis kit providers), recent developments and an informed future outlook.  Aldevron  APExBIO  Biomay  Bio-Synthesis  CELLSCRIPT  eTheRNA  Eurogentec  Jena Biosciences  New England Biolabs  Thermo Fisher Scientific  TriLink BioTechnologies For additional details, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • yamunapharmacy
  • Are you peeking for the top Indian herbal product franchise? Your wait is over! We are looking for distributors and suppliers who want to expand their businesses through third-party manufacturing or medicine franchise. For more details, go to https://yamunapharmacy.com/business-opportunities/ [more]
  • rekha
  • Peptide API CMO Market Trends, Industry Analysis 2022-28 The global peptide api cmo market was estimated to be valued US$ XX Mn in 2021 and poised to grow at significant CAGR over 2022-2028 Glance our 200 slides market research and competitive intelligence research report, 25 Tables and 65 Figures and other qualitative sections with an in-depth TOC on “Global Peptide API CMO Market: By Product Type (Peptide Generic API, Peptide NCEs), By Therapeutic area (Oncology, Cardiovascular Disorders, metabolic Disorders, CNS Disorders, Respiratory Disorders, Gastrointestinal Disorders, Anti-infective, Dermatology, Renal Disorders, Others), End User (Pharmaceutical Companies, Biopharmaceutical Companies) and Geography- Global/Region/Country Forecast to 2028”. [more]
  • jameshebrew
  • THE GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET FOR HEALTHCARE TO GROW AT AN ANNUALIZED RATE OF ~14%, TILL 2035 The global demand for biologics currently holds the largest share in the non-viral drug delivery domain and is expected to show the similar trend in the coming years. Further, the nanoparticle and extracellular vesicles emerged as the star as per the BCG matrix during our research. In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry. It is also interesting to note that the polymer has a low growth rate but a higher market share. Hence, it is considered as the cash cow in the current time. The ongoing research for various types of technological modifications is expected to lead to the development of newer generation of non-viral drug delivery systems that are anticipated to hold a significant share in the future market. Over the past few years, players engaged in the domain of non-viral drug delivery have signed various partnerships aiming in efficient intracellular delivery of drugs. During our research, we observed that majority of the partnership deals (42%) were technology licensing deals followed by technology evaluation agreement (20%). Additionally, intracellular drug delivery systems market has witnessed seven instances of acquisitions and mergers in the given time period. This trend reflects that companies are continuously striving to expand their existing service offerings. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market/request-sample.html The global demand for biologics currently holds the largest share in the non-viral drug delivery domain. However, the demand for small molecule in the long term is anticipated to increase as the new advances the medical field would soon allow the intracellular delivery of drugs orally. For additional details, please visit https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • vamshee
  • https://precisionbusinessinsights.com/market-reports/global-protein-a-resin-market/ Protein A Resin Market by Matrix Type (Agarose based, Glass or Silica, Organic Polymer), Application (Immuno Precipitation, Antibody Purification), and End User (Biotechnology and Pharmaceutical industries, Research Laboratories) and Geography.
  • latestmarketnews
  • ESG is a vital component of opportunity capture, vulnerability management, and sustainability. Environmental and social issues are significant and relevant in different ways depending on the assessed organization, industry, and locality. Governance measures how well an organization is managed and how well the interests of various stakeholders are protected. The global pharmaceutical business along with a fair return demands sustainability and environmentally beneficial corporate practices. Why is it important to have ESG? The abbreviation ESG stands for environmental, social and corporate governance. It is a measurement that takes into account a company's social and environmental impact on the global community. It brings awareness to the different climate issues that are occurring and encourages businesses to adopt practices and policies that are better for the environment. ESG not only helps businesses by attracting a more diverse workforce to bring in new ideas, but it also helps businesses have a greater positive impact on our world. Read More @ https://astra.grandviewresearch.com/pharmaceutical-manufacturing-industry-esg-outlook [more]
  • jameshebrew
  • Given the potential of digital twins to replicate the physical world in a digital layout, as well as their ability to provide real-time outputs, while gathering constant inputs from the real-world, such products have generated significant interest within the healthcare domain Roots Analysis has announced the addition of “Digital Twins Market, 2022-2035” report to its list of offerings. Since the first application of the digital twin concept for manufacturing in 2002, it has emerged as a crucial component for companies to achieve higher efficiency in their production processes. According to the US-based Digital Twin Consortium, digital twins hold the potential to reduce clinical trial expenditure, turnaround times, staffing expenses and plan medical intervention. Digital twin technology companies are currently engaged in the development of products which are intended for numerous applications, such as asset / process management, personalized treatment and surgical planning. Key Market Insights Over 35 digital twins are presently available in this market space More than 60% of the digital twins offered by industry players are body part twins; these products are primarily intended for asset / process management, personalized treatment and surgical planning. Further, majority of the products that are currently under development are focused on the treatment of indications, such as cardiovascular disorders, metabolic disorders, and neurological disorders. More than 30 players currently claim to be engaged in the digital twin domain Majority of the players engaged in this industry are small firms (11-50 employees, 37%), followed by very large players (10,000+ employees, 22%), large players (501-10,000 employees, 19%), mid-sized players (51-500 employees, 13%) and very small companies (2-10 employees, 9%). Additionally, nearly 70% of the developers are based in Europe, followed by those based in North America (28%). Partnership activity for digital twins witnessed a CAGR of over 15%, in the past three years More than 50% of the partnerships have been signed since January 2020; of these, four partnerships were inked in the year 2022. Technology integration agreements have emerged as the most popular (30%) type of partnership model in the market, followed by technology utilization agreements (23%). Nearly USD 6 billion invested across the globe to advance digital twins focused initiatives A steady increase has been observed in funding activity since 2020, with the maximum number of instances (10) being reported in the year 2021. In fact, more than 90% of the total investment (in terms of the amount invested) was made in the last two years alone (2021- 2022). Of the amount raised in 2022, about USD 4.2 billion was contributed by the IPO of Babylon. Berkus start-up valuation analysis has been performed to evaluate start-ups in this domain The framework enables valuation of start-ups, based on several key success / risk factors . The key factors are assigned monetary values based on the qualities / risks possessed by a particular player. At the end, all valuations were added to calculate the final valuation of the company. Players based in North America are anticipated to capture nearly 30% of the market share by 2035 The overall digital twin market is expected to be primarily driven by the growing interest towards automation and prognostic systems. The estimates in our report suggest that digital twins intended to treat cardiovascular disorders are expected to hold 32% share of the market in 2035. It is interesting to mention that market for digital twins intended to serve pharmaceutical companies and medical device manufacturers, collectively, hold over 60% of the market share in 2035. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/digital-twins-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of digital twins for the healthcare domain?  Which type of digital twin is most commonly offered by developers engaged in this market space?  What is the relative competitiveness of different players engaged in the digital twins domain?  What is the likely valuation of start-ups involved in the development of digital twins for the healthcare sector?  What is the present and likely future demand for digital twins in the overall healthcare sector?  What are the anticipated future trends related to digital twins in the healthcare domain?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the digital twins market in the healthcare domain has been analyzed across the following segments:  Therapeutic Area  Cardiovascular Disorders  Metabolic Disorders  Orthopedic Disorders  Other Disorders  Type of Digital Twin  Process Twins  System Twins  Whole Body Twins  Body Part Twins  Area of Application  Asset / Process Management  Personalized Treatment  Surgical Planning  Diagnosis  Other Applications  End Users  Pharmaceutical Companies  Medical Device Manufacturers  Healthcare Providers  Patients  Other End Users  Key Geographical Regions  North America  Europe  Asia  Latin America  Middle East and North Africa  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations) and an informed future outlook.  Babylon  ExactCure  ImmersiveTouch  Navv Systems  ThoughtWire  Unlearn.AI For additional details, please visit https://www.rootsanalysis.com/reports/digital-twins-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Flow Cytometry Service Market, 2022-2035 2. Gene Editing beyond CRISPR Market, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact Information Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com [more]
  • Healthcare_medical
  • Healthcare Analytical Testing Services Market Current and Future Industry Trends, 2022 - 2027 https://bit.ly/3IObJPk The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4% during the forecast period. Growth in the market is driven by the growing production and development of pharmaceuticals, biopharmaceuticals, and biologics, as well as the increasing number of clinical trials. The market is competitive and less fragmented. At the top with a large number of leading market players based in developed countries or serve specific end-users or regions rather than offering all services enlisted under healthcare analytical testing. Prominent players in the healthcare analytical testing services market include Eurofins Scientific (Luxembourg), LabCorp (US), SGS (Switzerland), Charles River Laboratories (US), and WuXi AppTec (China). Companies in the healthcare analytical testing services market have adopted strategies such as partnerships, agreements, acquisitions, service launches as well as expansions to enhance their presence in the healthcare analytical testing services market. [more]
First Previous 1 2 3 4 5 6 7 8 9 10 Next Last